- This topic has 2 replies, 2 voices, and was last updated 2 years, 1 month ago by
.
-
Posts
-
-
Enrollment has resumed in Eloxx’s trial of ELX-02 for CF in Israel and Europe — but not in the U.S. — after being suspended amid the COVID-19 crisis. Click here to learn more.
What do you think of this news?
-
-
I agree with Steff. This is an exciting drug showing much promise.
Eloxx. can you do some stage 2 trials in Melbourne, Australia. Prof John Wilson of CF Unit, Alfred Hospital, is willing as is my wife who is heterozygous for G542X. She is an excellent person to trial the drug as she has complex effects of the failure of the ion (Chloride) transport and is a survivor of many failed treatments for her many issues. -
Indeed this is good news. Having one stop-codon mutation myself, I have been following several studies with read-through compounds with great interest, like aminoglycoside antibiotics and Ataluren (ptc124).
Unfortunately, although promising in vitro and in animal models, in vivo phase 2 studies have not been successful so far. But I think this is still an approach that could be revolutionar, not least because there many genetic diseases (for instance Duchenne) that could be cured with an effective read-through compound medication.
-
- You must be logged in to reply to this topic.
